Tiracizine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H563118

CAS#: 78816-67-8

Description: Tiracizine HCl is an anti-arrhythmia agent.

Chemical Structure

img
Tiracizine HCl
CAS# 78816-67-8
Instruction

Theoretical Analysis

Hodoodo Cat#: H563118
Name: Tiracizine HCl
CAS#: 78816-67-8
Chemical Formula: C21H26ClN3O3
Exact Mass: 403.17
Molecular Weight: 403.900
Elemental Analysis: C, 62.45; H, 6.49; Cl, 8.78; N, 10.40; O, 11.88

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tiracizine HCl; Tiracizine Hydrochloride; Bonnecor; AWD-19-166; AWD19166; AWD 19 166;

IUPAC/Chemical Name: ethyl (5-(dimethylglycyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbamate hydrochloride

InChi Key: XJWABFCDXKZWPV-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H25N3O3.ClH/c1-4-27-21(26)22-17-12-11-16-10-9-15-7-5-6-8-18(15)24(19(16)13-17)20(25)14-23(2)3;/h5-8,11-13H,4,9-10,14H2,1-3H3,(H,22,26);1H

SMILES Code: O=C(CN(C)C)N1C2=C(C=CC(NC(OCC)=O)=C2)CCC3=CC=CC=C13.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 403.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Galenko-Iaroshevskiĭ PA, Khankoeva AI, Uvarov AV, Bartashevich VV, Popov PB, Sirotenko DV, Boldin VB. [Correction of the cardiotoxic effect of the anti-arrhythmia agents with befol, sufan, and their combination]. Biull Eksp Biol Med. 1998 Jun;125(6):641-6. Russian. PubMed PMID: 9693756.

2: Oertel R, Richter K, Gramatté T, Kirch W. Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J Chromatogr A. 1998 Feb 27;797(1-2):203-9. PubMed PMID: 9542112.

3: Mishin IuI, Kliachkina IL, Ivashkin VT, Min'kova TI, Bannikova SD. [The anti-arrhythmia action of tiracizine in patients with ischemic heart disease and decreased myocardial contractile function]. Voen Med Zh. 1997 Jun;318(6):44-7. Russian. PubMed PMID: 9412062.

4: Galenko-Iaroshevskiĭ PA, Khankoeva AI, Uvarov AV, Reznikov AIu, Galygo DS, Bartashevich VV. [Comparative anti-arrhythmia activity of befol, lidocaine, and bonnecor]. Biull Eksp Biol Med. 1996 Dec;122(12):665-8. Russian. PubMed PMID: 9280469.

5: Zaslavskaia RM, Mirskiĭ BA, Diagilev II. [The efficacy of anti-arrhythmia therapy with bonnecor in middle-aged and elderly patients]. Klin Med (Mosk). 1996;74(2):30-2. Russian. PubMed PMID: 8772098.

6: Berndt A, Hoffmann C, Richter K, Oertel R, Vierkant A, Siegmund W. Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype. Br J Clin Pharmacol. 1995 Sep;40(3):287-8. PubMed PMID: 8527295; PubMed Central PMCID: PMC1365113.

7: Berndt A, Oertel R, Terhaag B, Richter K, Gramatté T. Pharmacokinetics of the antiarrhythmic agent tiracizine: steady state kinetics in comparison with single-dose kinetics. Biopharm Drug Dispos. 1995 Jul;16(5):427-41. PubMed PMID: 8527691.

8: Németh M, Varró A, Papp JG. Electrophysiological effects of tiracizin and its metabolites in dog cardiac Purkinje fibers. Gen Pharmacol. 1995 Jul;26(4):793-8. PubMed PMID: 7635254.

9: Berndt A, Gramatté T, Oertel R, Terhaag B, Richter K, Kirch W. Day-night variations in the renal excretion of the antiarrhythmic agent tiracizine and its metabolites. Chronobiol Int. 1995 Apr;12(2):135-40. PubMed PMID: 8653799.

10: Berndt A, Oertel R, Richter K, Terhaag B, Gramatté T. [Relative bioavailability of the antiarrhythmia agent, tiracizine and its metabolites]. Arzneimittelforschung. 1995 Mar;45(3):250-3. German. PubMed PMID: 7741778.

11: Fomichev VI, Smerdina IS, Preobrazhenskiĭ DV, Gorshkov VA. [Use of bonnecor in the treatment of ventricular arrhythmia]. Klin Med (Mosk). 1995;73(4):44-6. Russian. PubMed PMID: 7474818.

12: Berndt A, Gramatté T, Oertel R, Richter K, Terhaag B, Kirch W. Dose dependent tiracizine disposition in healthy volunteers: serum and urine kinetics and dose related ECG-changes. Eur J Drug Metab Pharmacokinet. 1994 Oct-Dec;19(4):359-68. PubMed PMID: 7737238.

13: Berndt A, Oertel R, Richter K, Gramatté T. Food Enhances Bioavailability of the New Antiarrhythmic Agent Tiracizine by Affecting its Hepatic First-Pass Metabolism: Evidence by Serum and Urine Metabolite Kinetics. Am J Ther. 1994 Jun;1(1):22-29. PubMed PMID: 11835063.

14: Paliani-Katsitadze NSh, Berdiaev SIu, Turilova AI, Kaverina NV, Likhosherstov AM. [A comparative study of the antiarrhythmic action of bonnecor and the mesidide derivatives of alpha-azacycloalkane carboxylic acids]. Eksp Klin Farmakol. 1994 May-Jun;57(3):15-7. Russian. PubMed PMID: 8049618.

15: Parkhomenko AN, Stepanenko AP, Beziuk NN, Nagnybeda EN, Deiak SI. [The efficacy of bonnecor in refractory ventricular tachycardia in a patient with ischemic heart disease]. Lik Sprava. 1994 Feb;(2):90-2. Russian. PubMed PMID: 8073734.

16: Stejfa M, Zeman K, Groch L, Bytesník J, Krausová R. [Tiracizine in the treatment of ventricular arrhythmia (preliminary study)]. Vnitr Lek. 1993 Jun;39(6):549-53. Czech. PubMed PMID: 8212608.

17: Smerdina IS, Fomichev VI, Nesvetov VN, Gorshkov VA, Preobrazhenskiĭ DV. [The pharmacodynamics of the new anti-arrhythmia preparation bonnecor based on the data from an acute drug test]. Kardiologiia. 1993;33(7):11-4, 3. Russian. PubMed PMID: 8309173.

18: Denisova SV, Sapozhkov AV. [The effect of bonnecor on blood coagulability and thrombocyte aggregation in transient myocardial ischemia]. Eksp Klin Farmakol. 1992 Nov-Dec;55(6):29-31. Russian. PubMed PMID: 1305870.

19: Kobrin VI, Vostrikov VA. [Effects of bonnecor on transmembrane potentials of cardiomyocytes of the ventricular contractile myocardium of the intact heart and ventricular fibrillation]. Kardiologiia. 1992 Jun;32(6):61-3. Russian. PubMed PMID: 1405299.

20: Kaverina NV, Sokolov SF. Pharmacology and clinical use of a new group of antiarrhythmic drugs: derivatives of tricyclic nitrogen-containing systems. Pharmacol Res. 1992 Apr;25(3):217-25. Review. PubMed PMID: 1518765.